Mahmoud, D. B., M. H. Shukr, and E. R. Bendas, "In vitro and in vivo evaluation of self-nanoemulsifying drug delivery systems of cilostazol for oral and parenteral administration.", International journal of pharmaceutics, vol. 476, issue 1-2, pp. 60-69, 2014.
Elbary, A. A., E. R. Bendas, A. A. Ramadan, and D. a Mostafa, "Pharmaceutical and pharmacokinetic evaluation of a novel fast dissolving film formulation of flupentixol dihydrochloride.", AAPS PharmSciTech, vol. 15, issue 6, pp. 1603-10, 2014.
Bendas, E. R., and A. A. Abdelbary, "Instantaneous enteric nano-encapsulation of omeprazole: pharmaceutical and pharmacological evaluation.", International journal of pharmaceutics, vol. 468, issue 1-2, pp. 97-104, 2014.
Sherif, S., E. R. Bendas, and S. Badawy, "The clinical efficacy of cosmeceutical application of liquid crystalline nanostructured dispersions of alpha lipoic acid as anti-wrinkle.", European journal of pharmaceutics and biopharmaceutics , vol. 86, issue 2: Elsevier B.V., pp. 251-9, 2013/09//, 2014. AbstractWebsite

Topical 5% alpha lipoic acid (ALA) has shown efficacy in treatment of photo-damaged skin. The aim of this work was to evaluate the potential of poloxamer (P407) gel as a vehicle for the novel lipid base particulate system (cubosome dispersions) of ALA. Cubosome dispersions were formulated by two different approaches, emulsification of glyceryl monoolein (GMO) and poloxamer (P407) in water followed by ultrasonication, and the dilution method using a hydrotrope. Three different concentrations of GMO were used to formulate the cubosome dispersions using the first method, 5% (D1), 10% (D2) and 15% w/w (D3). In the second technique an isotropic liquid was produced by combining GMO with ethanol, and this isotropic liquid was then diluted with a P407 solution (D4). The dispersions were characterized by zeta potential, light scattering techniques, optical and transmission electron microscopy, encapsulation efficiency and in vitro drug release. Results showed that D4 was not a uniform dispersion and that D1, D2 and D3 were uniform dispersions, in which by increasing the GMO content in the dispersion, the size of the cubosomes decreased, zeta potential became more negative, encapsulation efficiency increased up to 86.48% and the drug release rate was slower. P407 gels were prepared using the cold method. Two concentrations of P407 gel were fabricated, 20 and 30% w/w. P407 gels were loaded with either ALA or dispersions containing ALA cubosomes. P407 gels were characterized by critical gelation temperature, rheological measurements and in vitro drug release studies. Results suggested that by increasing P407 concentration, the gelation temperature decreases and viscosity increases. Drug release in both cases was found to follow the Higuchi square root model. Gel loaded with ALA cubosomes provided a significantly lower release rate than the gel loaded with the un-encapsulated ALA. A double blinded placebo controlled clinical study was conducted, aiming to evaluate the efficacy as an anti-wrinkle agent and volunteer's satisfaction upon application of topical 30% P407 gel loaded with ALA cubosomes. Results indicated reduction in facial lines, almost complete resolution of fine lines in the periorbital region and upper lip area and overall improvement in skin color and texture in most volunteers. There were no instances of irritation, peeling or other apparent adverse side effects.

Bendas, E. R., and E. B. Basalious, "{Rapidly disintegrating vagina retentive cream suppositories of progesterone: development, patient satisfaction and in vitro / in vivo studies}", Pharmaceutical Development and Technology, vol. 00, no. 00: Informa Healthcare USA, Inc, pp. 1–8, 2015. AbstractWebsite

Our objective was to develop novel vagina retentive cream suppositories (VRCS) of progesterone having rapid disintegration and good vaginal retention. VRCS of progesterone were prepared using oil in water (o/w) emulsion of mineral oil or theobroma oil in hard fat and compared with conventional vaginal suppositories (CVS) prepared by hard fat. VRCS formulations were tested for content uniformity, disintegration, melting range, in vitro release and stability studies. The most stable formulation (VRCS I) was subjected to scaling-up manufacturing and patients’ satisfaction test. The rapid disintegration, good retentive properties are applicable through the inclusion of emulsified theobroma oil rather than hydrophilic surfactant into the hard fat bases. The release profile of progesterone from VRCS I showed a biphasic pattern due to the formation of progesterone reservoir in the emulsified theobroma oil. All volunteers involved in patients’ satisfaction test showed high satisfactory response to the tested formulation (VRCS). The in vivo pharmacokinetic study suggests that VRCS of progesterone provided higher rate and extent of absorption compared to hard fat based suppositories. Our results proposed that emulsified theobroma oil could be promising to solve the problems of poor patients’ satisfaction and variability of drug absorption associated with hard fat suppositories.

Souaya, E. R., M. M. H. Khalil, E. H. Ismail, E. R. Bendas, and O. S. Neaz, "Synthesis and Characterization of Ternary Complexes of certain Hydroxyl Acids and their Biological Applications", Research Journal of Pharmaceutical , Biological and Chemical Sciences, vol. 5, issue 18, pp. 18-30, 2014.
Sherif, S., E. R. Bendas, and S. Badawy, "The Design and Evaluation of Novel Encapsulation Technique for Topical Application of Alpha Lipoic Acid ", Journal of Advanced Pharmaceutical Research, vol. 4, issue 1, pp. 13 - 22, 2013///. Abstract

n/a

Elbary, A. A., A. A. Ramadan, E. R. Bendas, D. Abd, and E. Mostafa, "FORMULATION AND EVALUATION OF TASTE MASKED RAPIDLY DISINTEGRATING TABLET CONTAINING FLUPENTIXOL DIHYDROCHLORIDE", INTERNATIONAL RESEARCH JOURNAL OF PHARMACY, vol. 2, issue 9, pp. 58 - 64, 2011///. Abstract

n/a

Bendas, E. R., M. A. A. Kassem, S. Esmat, and M. H. M. El-Komy, "Efficacy of topical griseofulvin in treatment of tinea corporis", Mycoses,, vol. 49, issue 3, pp. 232–235, 2006. griseofulvin_publication-ehab.pdf
El-Nabarawi, M. A., E. R. Bendas, R. T. a El Rehem, and M. Y. S. Abary, "Transdermal drug delivery of paroxetine through lipid-vesicular formulation to augment its bioavailability.", International journal of pharmaceutics, vol. 443, issue 1-2: Elsevier B.V., pp. 307 - 17, 2013/02//. AbstractWebsite

Paroxetine (PAX) is the most potent serotonin reuptake blocker antidepressant clinically available. This study is aimed to reduce the side effects accompanied with the initial high plasma concentration after oral administration of PAX and fluctuations in plasma levels and also to decrease the broad metabolism of the drug in the liver by developing and optimizing liposomal transdermal formulation of PAX in order to improve its bioavailability. PAX liposomes were prepared by reverse phase evaporation technique using lecithin phosphatidylcholine (LPC), cholesterol (CHOL) and drug in different molar ratios. The prepared liposomes were characterized for size, shape, entrapment efficiency and in vitro drug release. The studies demonstrated successful preparation of PAX liposomes. The effect of using different molar ratios of (LPC:CHOL) on entrapment efficiency and on drug release was studied. Liposomes showed percentage entrapment efficiency (%EE) of 81.22 ± 3.08% for optimized formula (F5) which composed of (LPC:CHOL, 7:7) and 20mg of PAX, with average vesicle size of 220.53 ± 0.757 nm. The selected formula F5 (7:7) was incorporated in gel bases of HPMC-E4M (2%, 4%, and 6%). The selected formula of PAX liposomal gel of HPMC-E4M (2% and 4%) were fabricated in the reservoir type of transdermal patches and evaluated through in vitro release. After that the selected formula of PAX liposomal gel transdermal patch was applied to rabbits for in vivo bioavailability study in comparison with oral administration of the marketed PAX tablet. An HPLC method was developed for the determination of PAX in plasma of rabbits after transdermal patch application and oral administration of the marketed PAX tablets of 20mg dose. The intra- and inter-day accuracy and precision were determined as relative error and relative standard deviation, respectively. The linearity was assessed in the range of 5-200 ng/ml. Pharmacokinetic parameters were determined as the C(max) of PAX liposomal transdermal patch was found to be 92.53 ng/ml at t(max) of 12h and AUC(0-48) was 2305.656 ngh/ml and AUC(0-∞) was 3852.726 ngh/ml, compared to the C(max) of 172.35 ng/ml after oral administration of the marketed PAX tablet with t(max) of 6h and AUC(0-24) was 1206.63 ngh/ml and AUC(0-∞) was 1322.878 ngh/ml. These results indicate improvement of bioavailability of the PAX after liposomal transdermal patch application and sustaining of the therapeutic effects compared to oral administration.